ImmunityBio (IBRX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$256.9 million.
- ImmunityBio's Enterprise Value fell 9856.39% to -$256.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.9 million, marking a year-over-year decrease of 9856.39%. This contributed to the annual value of -$148.8 million for FY2024, which is 4392.11% up from last year.
- As of Q3 2025, ImmunityBio's Enterprise Value stood at -$256.9 million, which was down 9856.39% from -$152.7 million recorded in Q2 2025.
- In the past 5 years, ImmunityBio's Enterprise Value registered a high of -$49.0 million during Q2 2023, and its lowest value of -$318.9 million during Q4 2021.
- Its 5-year average for Enterprise Value is -$148.6 million, with a median of -$129.4 million in 2024.
- As far as peak fluctuations go, ImmunityBio's Enterprise Value surged by 6560.3% in 2022, and later plummeted by 34260.62% in 2024.
- ImmunityBio's Enterprise Value (Quarter) stood at -$318.9 million in 2021, then soared by 65.6% to -$109.7 million in 2022, then crashed by 141.99% to -$265.4 million in 2023, then surged by 43.92% to -$148.8 million in 2024, then crashed by 72.6% to -$256.9 million in 2025.
- Its Enterprise Value was -$256.9 million in Q3 2025, compared to -$152.7 million in Q2 2025 and -$60.6 million in Q1 2025.